Last updated: July 2, 2026
EFIDAC 24 chlorpheniramine maleate market dynamics, sales trajectory, and competitive outlook
EFIDAC 24 (chlorpheniramine maleate) is a legacy, off-patent, over-the-counter (OTC) style antihistamine product whose market trajectory is driven by regional OTC demand, pack-size economics, pharmacy channel mechanics, and generic substitution rather than branded premium pricing. Financial performance typically tracks household brand availability, retailer formularies, promotional intensity, and adverse-event and regulatory perception of first-generation antihistamines. In the absence of verified, drug-specific financial disclosures and regulator-provided sales/volume reporting tied to the specific SKU “EFIDAC 24,” the only accurate “market dynamics” statement is that its value pool is structurally exposed to generic price compression and supply stability risk common to older small-molecule antihistamines.
What drives EFIDAC 24 chlorpheniramine maleate demand in pharmacy and OTC channels?
Demand drivers
- Seasonality: Higher winter/early spring sales in many geographies due to allergic rhinitis and common cold symptom demand.
- Channel placement: Shelf placement and retailer promotions generally matter more for first-generation antihistamines than differentiated clinical positioning.
- Substitution elasticity: High, because chlorpheniramine maleate is typically available as generics across multiple manufacturers.
- Product format and dosing convenience: “24” branding implies extended dosing interval in some markets, but market outcomes depend on actual label dosing and dosing adherence versus immediate-release competitors.
Competitive dynamics
- Multi-source reality: Market share is usually contested on price and pack availability, not on IP.
- Retail promotions: Margin is often traded for volume during allergy seasons.
- Regulatory messaging: Safety communications (sedation, anticholinergic effects) can shift preference toward newer antihistamines when they are available at similar price points.
Price-mix mechanics
- Pack-size strategy: Higher volume packs often reduce unit pricing and increase share.
- Promotion frequency: Brand owners with manufacturing scale can sustain promotional activity without losing profitability as quickly as smaller suppliers.
How does the generic substitution risk affect EFIDAC 24 pricing and margins?
Substitution impact
- Chlorpheniramine maleate is an old active ingredient; in most jurisdictions it is outside composition-of-matter patent protection.
- That creates a structural floor on pricing: retailers and wholesalers favor the lowest-cost supply that can reliably meet demand.
Margin compression pattern
- Lead competitor set: Generics with equivalent dose and similar patient-facing claims (e.g., duration-of-effect positioning) typically become the benchmark.
- Contracting behavior: Pharmacy chains and distributors negotiate annual or seasonal pricing, then rotate supply.
- Procurement concentration: If the market is supplied through a limited number of wholesalers, the distribution network can amplify price wars.
Commercial implication
- Expect financial trajectory to be dominated by volume stability and manufacturing cost control rather than by brand-driven price premiums.
What is the Orange Book status for EFIDAC 24 chlorpheniramine maleate?
No Orange Book status can be stated for “EFIDAC 24 chlorpheniramine maleate” based on the information provided. The Orange Book is FDA’s U.S. publication system for approved drug products with patents and exclusivities; without a confirmed U.S. NDA/ANDA mapping for this exact branded SKU, listing status cannot be accurately reported.
When does EFIDAC 24 lose exclusivity, and what does that imply for future revenue?
No exclusivity timelines can be stated for “EFIDAC 24 chlorpheniramine maleate” without a verified reference to a specific FDA approval (NDA/ANDA), country-specific marketing authorization, or a patent/exclusivity register tied to that branded product. For chlorpheniramine maleate as a molecule, exclusivity typically reflects formulation- or packaging-specific rights, but those must be itemized by product and jurisdiction to be enforceable and analytically meaningful.
Which patents cover chlorpheniramine maleate formulations like EFIDAC 24?
No EFIDAC 24–specific patent estate can be produced from the provided prompt. For first-generation antihistamines broadly, generic entrants often rely on:
- Composition and manufacturing know-how (usually not blocked post-original filing eras),
- Formulation process claims that may still exist in some jurisdictions,
- Method-of-use claims that may not be valid for symptom relievers depending on label and claim scope.
A legally actionable patent landscape requires named patents, assignees, jurisdictions, and claim sets. None are present here.
What formulation and delivery-system IP risks matter for EFIDAC 24 “24” dosing?
If “24” indicates sustained or prolonged symptom relief, the key IP and regulatory risks in such products typically include:
- Release profile equivalence: sustained-release technologies can face formulation-specific patent or data-exclusivity barriers in some markets.
- Bioavailability and dose justification: regulators may require bioequivalence or additional bridging data if the release profile differs from reference products.
- Label claim support: “24-hour” claims are often scrutinized for substantiation, and inaccurate claims can trigger regulatory actions.
Without a validated product dossier and reference comparator, no concrete “protected formulation” and “entry risk” can be stated for EFIDAC 24.
What generic launch scenarios exist for chlorpheniramine maleate products like EFIDAC 24?
For chlorpheniramine maleate products, typical generic launch scenarios include:
- ANDA-style generic equivalence where an established reference product exists (U.S.), or
- National abridged registrations in other jurisdictions where bioequivalence requirements are standardized and the active substance is longstanding.
Commercial risk profile for a branded product is usually:
- Fast share loss after generics establish supply, driven by tendering and pharmacy substitution.
- Trading down by payers that support OTC cost minimization (in some markets via reimbursement or pharmacy-funded programs).
No EFIDAC 24 launch/ANDA history is provided, so no scenario can be tied to actual filings.
What regulatory milestones typically shape the market for older antihistamines like chlorpheniramine maleate?
Regulatory milestones that can affect market dynamics include:
- Label updates reflecting safety communications (sedation, driving impairment warnings, pediatric restrictions where applicable).
- OTC classification changes that alter access and marketing restrictions.
- Quality/CMC enforcement that can remove supply from the market if manufacturing sites fail inspection.
Because chlorpheniramine maleate has a long regulatory history, the regulatory impact is usually incremental and supply-side, not a one-off exclusivity event.
No jurisdiction-specific EFIDAC 24 regulatory record is available in the prompt.
How do safety communications and label restrictions affect first-generation antihistamines’ financial trajectory?
First-generation antihistamines can experience:
- Segment preference shifts toward second-generation agents when pricing narrows and access is easy.
- Conversion from self-care to clinician-guided use in some markets.
- Seasonal volatility when media and public health guidance heighten awareness of sedation-related risks.
Financial trajectory is generally protected by:
- Price leadership from generics,
- Low-cost packs used as household OTC staples.
A branded SKU like EFIDAC 24 can be vulnerable when:
- Competitors offer similar “daytime/non-drowsy” positioning,
- Retailers reduce shelf allocation.
No EFIDAC 24-specific sales or market-share curve is provided to quantify effects.
What is the competitive landscape for chlorpheniramine maleate products, and how concentrated is supply?
No market concentration metrics, named competitor SKUs, or sourcing/manufacturing network data are provided. In general for chlorpheniramine maleate OTC products:
- Competition is high across multiple generic manufacturers.
- Concentration depends on which firms hold the manufacturing licenses, contract packaging capacity, and distributor relationships in each geography.
A precise competitive map for EFIDAC 24 requires product registry identifiers and distributor listings by country, which are not supplied.
How does EFIDAC 24 compare with other allergy and cold symptom OTC antihistamines?
Typical comparative dynamics for first-generation chlorpheniramine products versus second-generation antihistamines:
- Onset vs sedation tradeoff: first-generation agents often cause more sedation; second-generation options often carry “non-drowsy” preferences.
- Price: first-generation generics often stay cheaper, supporting volume even when preference shifts.
- Usage pattern: first-generation agents can remain preferred for night-time use depending on label guidance.
No EFIDAC 24 formulation, label claims, or countryspecific comparator basket is provided, so no quantified competitive comparison can be made.
What does the financial trajectory of chlorpheniramine maleate OTC products usually look like?
In mature OTC antihistamines:
- Revenue growth is usually modest and driven by population growth, channel expansion, and seasonal elasticity, not by IP-led differentiation.
- Margins trend down due to price competition and promotion cycles.
- Share tends to be stable only for suppliers with strong supply reliability and cost advantage.
For EFIDAC 24 specifically, a financial trajectory cannot be quantified without:
- Country-specific sales history,
- Manufacturer or brand owner financial disclosure,
- Pharmacy scanner data and wholesaler shipment data tied to this exact branded SKU.
No such data is included.
Key Takeaways
- EFIDAC 24 (chlorpheniramine maleate) is exposed to the core economics of mature OTC antihistamines: generic substitution, seasonal demand, and distribution-driven share.
- The market’s financial trajectory is typically volume-led and price-compressed, with profitability tied to manufacturing scale and promotional discipline.
- No product-specific exclusivity, Orange Book status, patent estate, or sales trajectory metrics can be asserted from the information provided.
FAQs
- How do “24-hour” dosing claims affect regulatory scrutiny for chlorpheniramine maleate products?
- What OTC channel metrics (rate of repeat purchase, seasonal uplift, and shelf share) best predict chlorpheniramine maleate revenue performance?
- Do sustained-release chlorpheniramine maleate formulations face higher generic entry barriers than immediate-release products?
- How do safety labeling updates for sedation and anticholinergic effects influence antihistamine switching behavior?
- What procurement and tender practices most influence generic penetration of OTC antihistamines in community pharmacies?
References
No sources are cited because no verifiable EFIDAC 24 product registry identifiers, FDA/Orange Book records, patent numbers, or sales/market data were provided in the prompt.
